At Memorial Sloan Kettering (MSK), we're not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we're driving excellence and improving outcomes. We're treating cancer, one patient at a time. Join us and make a difference every day.
In compliance with applicable New York and New Jersey State regulatory authorities, COVID-19 vaccination (2 doses of either the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine) is mandatory for all MSK employees, contingent workers, and volunteers. Exceptions are permitted for those employees who request and receive an approved medical or fully remote exemption.
*Staff working at a MSK New Jersey location must be up to date with COVID-19 vaccination, which includes having completed the primary COVID-19 vaccination series and booster once eligible as mandated by New Jersey State. All New Jersey staff not yet eligible for a booster must receive a booster within 3 weeks of becoming eligible as a condition of continued employment at MSK.
Note: Individuals are eligible to receive a COVID-19 booster five months after receiving the second dose of either the Pfizer or Moderna vaccine or two months after the J&J vaccine.
We currently have a postdoctoral position available in the Jonathan Coleman Laboratory in the Department of Surgery at MSKCC. The laboratory's focus is on developing and translating a local ablation therapy called Vascular targeted photodynamic therapy (VTP) for the treatment of cancers as well as assessing its immune modulatory mechanism.
VTP is being developed to treat multiple types of cancers including patients with prostate, urothelial and lung cancers. Dr Coleman is leading multiple clinical trials at MSKCC and other centers. Our laboratory performs efficacy and safety studies of VTP and investigates its impact on tumor microenvironment to understand its immune modulatory effect. This will help develop combination of VTP/immune therapy leading to better clinical outcome. We use both syngeneic preclinical models as well as patient derived xenograft/organoids models developed in the lab to assess treatment effect. In addition, we analyze patient samples from pre- and post-treatment using flow cytometry, genomics and single cell RNA-seq to understand disease biology and treatment effects.
Responsibilities include working directly with the senior PhD (lab manager) to design, develop, and execute bench experiments and performing data management. Additionally, he/she will analyze experimental results to derive logical conclusions, draft experimental procedures, prepare manuscripts pertaining to research work, and maintain detailed laboratory records.
The ideal candidate will have a PhD with a background in immunotherapy/immunology, a passion for science, and a desire to advance the understanding and treatment of cancer. A highly organized and self-directed individual with strong interpersonal skills and the ability to work in a dynamic environment is desired. The candidate should have experience with and be willing to work with mouse models and should be comfortable with the handling of human tissue samples.
Please include CV, bibliography, brief statement of research interests, and names and details of three references in your application.
At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes. For the 28th year, MSK has been named a top hospital for cancer by U.S. News & World Report. We are proud to be on Becker’s Healthcare list as one of the 150 Great Places to Work in Healthcare in 2018, as well as one of Glassdoor’s Employees’ Choice Best Place to Work for 2018. We’re treating cancer, one patient at a time. Join us and make a difference every day.